MX2016007857A - Compuestos de indazol como agonistas del receptor de 5-ht4. - Google Patents
Compuestos de indazol como agonistas del receptor de 5-ht4.Info
- Publication number
- MX2016007857A MX2016007857A MX2016007857A MX2016007857A MX2016007857A MX 2016007857 A MX2016007857 A MX 2016007857A MX 2016007857 A MX2016007857 A MX 2016007857A MX 2016007857 A MX2016007857 A MX 2016007857A MX 2016007857 A MX2016007857 A MX 2016007857A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- receptor agonists
- indazole compounds
- formula
- relates
- Prior art date
Links
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con compuestos de indazol novedosos de la fórmula (I), incluyendo sus estereoisómeros y sus sales farmacéuticamente aceptables. La presente invención también se relaciona con métodos de elaboración de tales compuestos y de composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos de la presente invención son útiles en el tratamiento de varios trastornos que se relacionan con agonistas de receptores de 5-hidroxitriptamina 4 (5-HT4). (Ver fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN5852CH2013 | 2013-12-16 | ||
| PCT/IN2014/000116 WO2015092804A1 (en) | 2013-12-16 | 2014-02-24 | Indazole compounds as 5-ht4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016007857A true MX2016007857A (es) | 2016-09-07 |
| MX368017B MX368017B (es) | 2019-09-13 |
Family
ID=50736125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007857A MX368017B (es) | 2013-12-16 | 2014-02-24 | Compuestos de indazol como agonistas del receptor de 5-ht4. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9951045B2 (es) |
| EP (1) | EP3099675B1 (es) |
| JP (1) | JP6161823B2 (es) |
| KR (1) | KR101824154B1 (es) |
| CN (1) | CN105873920B (es) |
| AP (1) | AP2016009253A0 (es) |
| AU (1) | AU2014369085B2 (es) |
| BR (1) | BR112016013974B1 (es) |
| CA (1) | CA2932428C (es) |
| DK (1) | DK3099675T3 (es) |
| EA (1) | EA029951B1 (es) |
| ES (1) | ES2668873T3 (es) |
| IL (1) | IL245948B (es) |
| MX (1) | MX368017B (es) |
| NZ (1) | NZ720879A (es) |
| SG (1) | SG11201604849YA (es) |
| WO (1) | WO2015092804A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60804B1 (sr) | 2014-08-16 | 2020-10-30 | Suven Life Sciences Ltd | Proces proizvodnje 1-izopropil-3-{5-[1-(3-metoksipropil)piperidin-4-il]-[1,3,4]oksadiazol-2-il}-1h-indazol oksalata u velikom obimu |
| BR112017017275A2 (pt) | 2015-02-13 | 2018-04-17 | Suven Life Sciences Ltd | composto, composição farmacêutica, método para o tratamento e uso do composto |
| JP6900028B2 (ja) * | 2017-03-29 | 2021-07-07 | 国立大学法人帯広畜産大学 | パーキンソン病に併発した認知障害の治療剤 |
| EP3628660A1 (en) * | 2018-09-28 | 2020-04-01 | Université de Caen Normandie | Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases |
| EP4317141A1 (en) | 2022-08-04 | 2024-02-07 | Curia Spain S.A.U. | Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08502273A (ja) | 1992-10-13 | 1996-03-12 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５−ｈｔ▲下４▼レセプターアンタゴニスト用複素環式エステルまたはアミド |
| JPH08502741A (ja) | 1992-11-05 | 1996-03-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５−ｈｔ▲下４▼レセプターアンタゴニスト用のピペリジン誘導体 |
| DE60206952T2 (de) | 2001-10-22 | 2006-06-22 | Pfizer Inc. | Imidazopyridinverbindungen als 5-ht4-rezeptormodulatoren |
| MXPA05011270A (es) | 2003-04-21 | 2006-01-24 | Pfizer | Compuestos de imidazopiridina que tienen actividad agonista del receptor 5-ht4 y actividad antagonista del receptor 5-ht3. |
| ES2338882T3 (es) | 2003-11-24 | 2010-05-13 | Pfizer, Inc. | Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4. |
| DK1701951T3 (da) * | 2003-12-23 | 2010-06-07 | Serodus As | Modulatorer af perifere 5-HT receptorer |
| CA2588037A1 (en) * | 2004-12-22 | 2006-06-29 | Theravance, Inc. | Indazole-carboxamide compounds |
| ES2523459T3 (es) | 2005-02-25 | 2014-11-26 | Raqualia Pharma Inc | Derivados de benzisoxazol |
| US7906532B2 (en) | 2005-07-22 | 2011-03-15 | Pfizer Inc. | Indazole derivatives |
| ES2640752T3 (es) | 2010-02-12 | 2017-11-06 | Askat Inc. | Agonistas del receptor 5-HT4 para el tratamiento de la demencia |
| CN102762554A (zh) | 2010-02-16 | 2012-10-31 | 辉瑞大药厂 | 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 |
| PL2758394T3 (pl) * | 2011-09-19 | 2015-08-31 | Suven Life Sciences Ltd | Związki heteroarylowe jako ligandy receptora 5-HT4 |
-
2014
- 2014-02-24 ES ES14725246.4T patent/ES2668873T3/es active Active
- 2014-02-24 BR BR112016013974-7A patent/BR112016013974B1/pt active IP Right Grant
- 2014-02-24 JP JP2016539987A patent/JP6161823B2/ja active Active
- 2014-02-24 KR KR1020167015974A patent/KR101824154B1/ko not_active Expired - Fee Related
- 2014-02-24 NZ NZ720879A patent/NZ720879A/en not_active IP Right Cessation
- 2014-02-24 US US15/104,521 patent/US9951045B2/en active Active
- 2014-02-24 MX MX2016007857A patent/MX368017B/es active IP Right Grant
- 2014-02-24 WO PCT/IN2014/000116 patent/WO2015092804A1/en not_active Ceased
- 2014-02-24 SG SG11201604849YA patent/SG11201604849YA/en unknown
- 2014-02-24 CN CN201480068132.6A patent/CN105873920B/zh active Active
- 2014-02-24 EA EA201691252A patent/EA029951B1/ru unknown
- 2014-02-24 CA CA2932428A patent/CA2932428C/en active Active
- 2014-02-24 DK DK14725246.4T patent/DK3099675T3/en active
- 2014-02-24 EP EP14725246.4A patent/EP3099675B1/en active Active
- 2014-02-24 AP AP2016009253A patent/AP2016009253A0/en unknown
- 2014-02-24 AU AU2014369085A patent/AU2014369085B2/en not_active Ceased
-
2016
- 2016-05-31 IL IL245948A patent/IL245948B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014369085A1 (en) | 2016-06-30 |
| BR112016013974B1 (pt) | 2022-11-22 |
| CN105873920B (zh) | 2018-06-08 |
| US20160311797A1 (en) | 2016-10-27 |
| IL245948A0 (en) | 2016-08-02 |
| NZ720879A (en) | 2017-05-26 |
| KR20160075832A (ko) | 2016-06-29 |
| CA2932428A1 (en) | 2015-06-25 |
| IL245948B (en) | 2019-08-29 |
| DK3099675T3 (en) | 2018-05-22 |
| AU2014369085B2 (en) | 2017-02-23 |
| EA201691252A1 (ru) | 2016-12-30 |
| WO2015092804A1 (en) | 2015-06-25 |
| BR112016013974A8 (pt) | 2018-01-30 |
| SG11201604849YA (en) | 2016-07-28 |
| US9951045B2 (en) | 2018-04-24 |
| BR112016013974A2 (pt) | 2017-08-08 |
| ES2668873T3 (es) | 2018-05-22 |
| CA2932428C (en) | 2017-10-24 |
| MX368017B (es) | 2019-09-13 |
| JP6161823B2 (ja) | 2017-07-12 |
| JP2016540796A (ja) | 2016-12-28 |
| EA029951B1 (ru) | 2018-06-29 |
| EP3099675A1 (en) | 2016-12-07 |
| AP2016009253A0 (en) | 2016-06-30 |
| KR101824154B1 (ko) | 2018-03-14 |
| CN105873920A (zh) | 2016-08-17 |
| EP3099675B1 (en) | 2018-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| UA108442C2 (ru) | Индазолы | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| EA201590748A1 (ru) | Противовирусные соединения против rsv | |
| TN2015000034A1 (en) | Derivatives of azaindazole or diazaindazole type for treating pain | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| EA201700042A1 (ru) | Соединения имидазопиридазина | |
| TN2016000511A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. | |
| MX2014003584A (es) | Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides. | |
| MX2015012350A (es) | Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5ht4. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |